How India's weight-loss drugs could reshape global obesity fight.

Simple item page
dc.contributor.authorReuters
dc.date.accessioned2026-10-06T05:21:37Z
dc.date.available2026-10-06T05:21:37Z
dc.date.issued2026-03-19
dc.descriptionNewspaper Article
dc.description.abstractIndia could soon see wider access to weight-loss drugs following the expiry of a key patent, a move expected to drive down prices and trigger competition among local pharmaceutical firms. The patent on semaglutide-the active ingredient behind Novo Nordisk's popular drugs Wegovy and Ozempic-expires in India this week.
dc.identifier.citationReuters. (2026). How India's weight-loss drugs could reshape global obesity fight. Daily Monitor.
dc.identifier.urihttps://bdears.busitema.ac.ug/handle/123456789/10202
dc.language.isoen
dc.publisherDaily Monitor
dc.titleHow India's weight-loss drugs could reshape global obesity fight.
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Reuters-DM-19-03-2026.pdf
Size:
1.3 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
Faculty of Health Sciences